Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 mg » 10 mg (Expand Search), 2 mg (Expand Search), 15 mg (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 mg » 10 mg (Expand Search), 2 mg (Expand Search), 15 mg (Expand Search)
-
1841
-
1842
-
1843
-
1844
-
1845
-
1846
-
1847
-
1848
-
1849
-
1850
-
1851
-
1852
-
1853
-
1854
Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines.
Published 2013“…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”
-
1855
-
1856
-
1857
-
1858
-
1859
Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF
Published 2021“…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
-
1860
Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF
Published 2021“…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”